A 12 Week Treatment, Multi-Center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150 microg o.d.) Via a SDDPI in Patients With Moderate to Severe COPD, Using Salmeterol (50 microg b.i.d.) as an Active Comparator Delivered Via a DISKUS Inhaler.

Trial Profile

A 12 Week Treatment, Multi-Center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150 microg o.d.) Via a SDDPI in Patients With Moderate to Severe COPD, Using Salmeterol (50 microg b.i.d.) as an Active Comparator Delivered Via a DISKUS Inhaler.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms INSIST
  • Sponsors Novartis
  • Most Recent Events

    • 30 Nov 2015 Discrepancy in dates: EudraCT reports global end date as 09 Oct 2015 where as NCT reports as 01 Oct 2009. Retained it as per NCT as it is a reliable source.
    • 25 Dec 2010 Additional trial investigator (Rai K) identified as reported by Clinical Trials Registry - India.
    • 22 Sep 2010 Status changed from recruiting to completed, as results reported at ERS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top